These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 25729247)

  • 21. Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer.
    Yasue M; Sakamoto J; Teramukai S; Morimoto T; Yasui K; Kuno N; Kurimoto K; Ohashi Y
    Pancreas; 1994 Nov; 9(6):735-40. PubMed ID: 7846017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conditional survival of pancreatic ductal adenocarcinoma in surgical and nonsurgical patients: a retrospective analysis report from a single institution in China.
    Liao R; Yang J; Zhou BY; Li DW; Huang P; Luo SQ; Du CY
    World J Surg Oncol; 2015 Jun; 13():196. PubMed ID: 26048469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
    Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
    Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
    J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Changes and Clinical Significance of Preoperative and Postoperative Serum CEA and CA19-9 in Gastric Cancer.
    Jing R; Cui M; Ju S; Pan S
    Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.
    Piagnerelli R; Marrelli D; Roviello G; Ferrara F; Di Mare G; Voglino C; Petrioli R; Marini M; Macchiarelli R; Roviello F
    Tumour Biol; 2016 Feb; 37(2):1959-66. PubMed ID: 26334620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer.
    Ishigami S; Natsugoe S; Hokita S; Che X; Tokuda K; Nakajo A; Iwashige H; Tokushige M; Watanabe T; Takao S; Aikou T
    J Clin Gastroenterol; 2001 Jan; 32(1):41-4. PubMed ID: 11154168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
    Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
    Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
    Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
    Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
    Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
    BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Tsuji A; Yamamura K; Kitano Y; Inoue R; Kaida T; Higashi T; Taki K; Imai K; Komohara Y; Beppu T; Takeya M; Baba H
    Int J Clin Oncol; 2016 Oct; 21(5):940-945. PubMed ID: 27023215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.
    Liu L; Xu H; Wang W; Wu C; Chen Y; Yang J; Cen P; Xu J; Liu C; Long J; Guha S; Fu D; Ni Q; Jatoi A; Chari S; McCleary-Wheeler AL; Fernandez-Zapico ME; Li M; Yu X
    Int J Cancer; 2015 May; 136(9):2216-27. PubMed ID: 25273947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis.
    Lin PC; Lin JK; Lin CC; Wang HS; Yang SH; Jiang JK; Lan YT; Lin TC; Li AF; Chen WS; Chang SC
    Int J Colorectal Dis; 2012 Oct; 27(10):1333-8. PubMed ID: 22426691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer.
    Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
    Anticancer Res; 2014 Jul; 34(7):3753-8. PubMed ID: 24982398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma.
    Nurmi AM; Mustonen H; Haglund C; Seppänen H
    Oncology; 2021; 99(11):686-698. PubMed ID: 34412062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.